DE69435267D1 - Proteinkinase C Inhibitoren - Google Patents

Proteinkinase C Inhibitoren

Info

Publication number
DE69435267D1
DE69435267D1 DE69435267T DE69435267T DE69435267D1 DE 69435267 D1 DE69435267 D1 DE 69435267D1 DE 69435267 T DE69435267 T DE 69435267T DE 69435267 T DE69435267 T DE 69435267T DE 69435267 D1 DE69435267 D1 DE 69435267D1
Authority
DE
Germany
Prior art keywords
inhibitors
protein kinase
kinase
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69435267T
Other languages
English (en)
Inventor
William Francis Heath Junior Heath
John Hampton Mcdonald Iii
Michael Paal
Gerd Ruhter
Schotten Theo
Wolfgang Stenzel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of DE69435267D1 publication Critical patent/DE69435267D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69435267T 1993-12-23 1994-12-14 Proteinkinase C Inhibitoren Expired - Lifetime DE69435267D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17374193A 1993-12-23 1993-12-23
US08/324,948 US5545636A (en) 1993-12-23 1994-10-18 Protein kinase C inhibitors

Publications (1)

Publication Number Publication Date
DE69435267D1 true DE69435267D1 (de) 2010-03-18

Family

ID=22633290

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69435267T Expired - Lifetime DE69435267D1 (de) 1993-12-23 1994-12-14 Proteinkinase C Inhibitoren

Country Status (6)

Country Link
US (1) US5545636A (de)
CY (1) CY2561B1 (de)
DE (1) DE69435267D1 (de)
ES (1) ES2337052T3 (de)
HK (1) HK1071289A1 (de)
ZA (1) ZA9410139B (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721230A (en) * 1993-05-10 1998-02-24 Hoffmann-La Roche Inc. Substituted pyrroles
US6511811B1 (en) * 1995-06-07 2003-01-28 The Regents Of The University Of California Protein kinase C antagonist related to insulin receptor
AU2217797A (en) * 1996-03-20 1997-10-10 Eli Lilly And Company Synthesis of indolylmaleimides
BR9710706A (pt) 1996-05-01 1999-08-17 Lilly Co Eli Tratamento terap-utico para doen-as relacionadas a vegf
US6232299B1 (en) 1996-05-01 2001-05-15 Eli Lilly And Company Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy
UA54427C2 (uk) * 1996-05-01 2003-03-17 Елі Ліллі Енд Компані Спосіб лікування очних захворювань, які пов'язані з фактором васкулярного ендотеліального росту
US6093709A (en) * 1996-08-22 2000-07-25 Eli Lilly And Company Therapeutic treatment for sexual dysfunctions
US5962446A (en) * 1996-08-30 1999-10-05 Eli Lilly And Company Therapetutic treatment for human T cell lymphotrophic virus type 1 infection
US6107327A (en) * 1996-08-30 2000-08-22 Eli Lilly And Company Therapeutic treatment for HIV infection
SE9603283D0 (sv) * 1996-09-10 1996-09-10 Astra Ab New compounds
TW472045B (en) 1996-09-25 2002-01-11 Astra Ab Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation
US5859261A (en) * 1997-03-20 1999-01-12 Eli Lilly And Company Synthesis of indolylmaleimides
US6093740A (en) * 1997-04-30 2000-07-25 Eli Lilly And Company Therapeutic treatment for skin disorders
US6147109A (en) * 1997-10-14 2000-11-14 The General Hospital Corporation Upregulation of Type III endothelial cell Nitric Oxide Synthase by HMG-CoA reductase inhibitors
AR017200A1 (es) 1997-12-23 2001-08-22 Astrazeneca Ab Compuestos inhibidores de la proteina cinasa c, sales farmaceuticamente aceptables de los mismos, formulaciones farmaceuitcas que los comprenden, usode las mismas y proceso para la sintesis de dichos compuestos
CA2227688C (en) 1998-01-16 2007-07-31 James W. Critchfield Methods and compositions for inhibition of viral replication
US6103713A (en) * 1998-03-05 2000-08-15 Eli Lilly And Company Therapeutic treatment for autoimmune diseases
US6225301B1 (en) 1998-03-05 2001-05-01 Eli Lilly And Company Therapeutic treatment for renal dysfunction
US6103712A (en) * 1998-03-05 2000-08-15 Eli Lilly And Company Therapeutic treatment for asthma
US6291446B1 (en) 1998-03-05 2001-09-18 Eli Lilly And Company Therapeutic treatment for cytomegalovirus infection
SE9800835D0 (sv) 1998-03-13 1998-03-13 Astra Ab New Compounds
US6180597B1 (en) * 1998-03-19 2001-01-30 Brigham And Women's Hospital, Inc. Upregulation of Type III endothelial cell nitric oxide synthase by rho GTPase function inhibitors
US6127401A (en) * 1998-06-05 2000-10-03 Cephalon, Inc. Bridged indenopyrrolocarbazoles
GB9828640D0 (en) * 1998-12-23 1999-02-17 Smithkline Beecham Plc Novel method and compounds
US6841567B1 (en) 1999-02-12 2005-01-11 Cephalon, Inc. Cyclic substituted fused pyrrolocarbazoles and isoindolones
US6492406B1 (en) 1999-05-21 2002-12-10 Astrazeneca Ab Pharmaceutically active compounds
US6284783B1 (en) 1999-06-09 2001-09-04 The Uab Research Foundation Use of bisindolylmaleimide compounds to induce Fas-mediated apoptosis
US6346625B1 (en) 1999-06-23 2002-02-12 Astrazeneca Ab Protein kinase inhibitors
US6399780B1 (en) 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
WO2001044247A2 (en) * 1999-12-16 2001-06-21 Eli Lilly And Company Agents and methods for the treatment of proliferative diseases
FR2805817B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation
US6355631B1 (en) * 2000-03-03 2002-03-12 Aventis Pharma S.A. Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation
IL161156A0 (en) * 2001-10-30 2004-08-31 Novartis Ag Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
US20080004332A1 (en) * 2002-03-07 2008-01-03 Alkon Daniel L Methods for alzheimer's disease treatment and cognitive enhancement
US20050065205A1 (en) * 2002-03-07 2005-03-24 Daniel Alkon Methods for Alzheimer's disease treatment and cognitive enhance
US6825229B2 (en) 2002-03-07 2004-11-30 Blanchette Rockefeller Neurosciences Institute Methods for Alzheimer's Disease treatment and cognitive enhancement
CA2393720C (en) * 2002-07-12 2010-09-14 Eli Lilly And Company Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride
US20040175384A1 (en) * 2003-12-12 2004-09-09 Mohapatra Shyam S. Protein kinase C as a target for the treatment of respiratory syncytial virus
US8592368B2 (en) 2003-12-19 2013-11-26 University Of South Florida JAK/STAT inhibitors and MAPK/ERK inhibitors for RSV infection
JP2007532506A (ja) * 2004-04-08 2007-11-15 ノバルティス アクチエンゲゼルシャフト 自己免疫疾患および拒絶反応の処置のためのタンパク質キナーゼｃ阻害剤
TW201206425A (en) 2004-05-18 2012-02-16 Brni Neurosciences Inst Treatment of depressive disorders
WO2006019851A1 (en) * 2004-07-23 2006-02-23 Eli Lilly And Company Methods for diagnosing and treating diabetic microvascular complications
CA2599611C (en) * 2005-02-09 2013-07-30 Chiang J. Li Meleimide derivatives, pharmaceutical compositions and methods for treatment of cancer
JP2008533172A (ja) * 2005-03-17 2008-08-21 ノバルティス アクチエンゲゼルシャフト チロシン／スレオニンキナーゼ阻害剤、特にＢ−ＲＡＦキナーゼ阻害剤としての、Ｎ−［３−（１−アミノ−５，６，７，８−テトラヒドロ−２，４，４ｂ−トリアザフルオレン−９−イル）−フェニル］ベンズアミド
EP1877424A4 (de) 2005-04-11 2010-09-29 Pharmagap Inc Inhibitoren von proteinkinasen und anwendungen davon
CA2617003A1 (en) * 2005-07-29 2007-02-08 Blanchette Rockefeller Neurosciences Institute Use of a pkc activator, alone or combined with a pkc inhibitor to enhance long term memory
CA2622867A1 (en) 2005-09-16 2007-03-22 Schering Corporation Pharmaceutical compositions and methods using temozolomide and a protein kinase inhibitor
GB0605691D0 (en) * 2006-03-21 2006-05-03 Novartis Ag Organic Compounds
US9974832B2 (en) 2007-02-09 2018-05-22 Cognitive Research Enterprises, Inc. Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and brain injury
CN101801969B (zh) * 2007-06-22 2014-10-29 艾科尔公司 治疗癌症的吲哚基吡咯烷
MX2009013815A (es) * 2007-06-22 2010-03-01 Arqule Inc Compuestos de quinazolinona y metodos de uso para los mismos.
EP2170870B1 (de) * 2007-06-22 2014-03-05 ArQule, Inc. Pyrrolidinon-, pyrrolidin-2,5-dion-, pyrrolidin- und thiosuccinimidderivate, zusammensetzungen und verfahren zur behandlung von krebs
US20090069377A1 (en) * 2007-09-12 2009-03-12 Protia, Llc Deuterium-enriched enzastaurin
WO2010144780A1 (en) * 2009-06-12 2010-12-16 University Of Kansas Compositions and methods for establishing and maintaining stem cells in an undifferentiated state
AU2011234644B2 (en) 2010-03-30 2014-07-17 Novartis Ag PKC inhibitors for the treatment of B-cell lymphoma having chronic active B-cell-receptor signalling
MX354820B (es) 2012-03-16 2018-03-21 Vitae Pharmaceuticals Inc Moduladores del receptor x del higado.
CN104203951B (zh) 2012-03-16 2016-11-02 生命医药公司 肝x受体调节剂
TR201806682T4 (tr) 2012-11-29 2018-06-21 Novartis Ag Farmasötik kombinasyonlar.
WO2014174478A1 (en) 2013-04-26 2014-10-30 Novartis Ag Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4808613A (en) * 1986-11-21 1989-02-28 Bristol-Myers Company Rebeccamycin derivative containing pharmaceutical composition
US4785085A (en) * 1986-11-21 1988-11-15 Bristol-Myers Company Rebeccamycin analogs
US4923986A (en) * 1987-03-09 1990-05-08 Kyowa Hakko Kogyo Co., Ltd. Derivatives of physiologically active substance K-252
IL89167A (en) * 1988-02-10 1994-02-27 Hoffmann La Roche Substituted pyrroles, their manufacture and pharmaceutical compositions containing them
US5380746A (en) * 1989-05-05 1995-01-10 Goedecke Aktiengesellschaft Bis-(1H-indol-3-YL)-maleinimide derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
US5292747A (en) * 1990-08-07 1994-03-08 Hoffman-La Roche Inc. Substituted pyrroles

Also Published As

Publication number Publication date
ZA9410139B (en) 1996-06-20
HK1071289A1 (en) 2005-07-15
US5545636A (en) 1996-08-13
ES2337052T3 (es) 2010-04-20
CY2561B1 (en) 2008-07-02

Similar Documents

Publication Publication Date Title
DE69435267D1 (de) Proteinkinase C Inhibitoren
NO974453D0 (no) Proteinkinase C-hemmere
DK0776895T3 (da) Proteinkinase C inhibitor
DE69627179D1 (de) Substituierte 2-anilino-pyrimidines verwendbar als protein kinase inhibitoren
DE69323185D1 (de) Proteinkinase c-inhibitor
NO942064D0 (no) yminhibitorer
NO992336D0 (no) Raf-kinase-inhibitorer
NO20002121D0 (no) Benzotiazol-protein-tyrosin-kinaseinhibitorer
ATE222240T1 (de) Hiv - protease inhibitoren
FI962315A (fi) Entsyymi-inhibiittorit
FI963597A0 (fi) Isoprenyylitransferaasi-inhibiittoreita
NO972930D0 (no) Fibronectin-adhesjonsinhibitorer
FI972160A (fi) Matriisimetalloproteaasi-inhibiittorit
DK0858452T3 (da) Thiazolderivater som proteinkinase C-inhibitorer
NO985577D0 (no) Alkyloksyaminosubstituerte fluorenoner og deres anvendelse som proteinkinase C-inhibitorer
DE69734817D1 (de) Neuartige amp-aktivierte proteinkinase
ZA949611B (en) Protein kinase C inhibitors
NO943494L (no) Eosinofil kjemotaksishemmer
BR9610514A (pt) Inibidores cicloantihelmínticos
ITMI930345A0 (it) N-acil-peptidi inibitori delle protein-chinasi
SI0657458T1 (en) Protein kinase C inhibitors
IL122092A0 (en) Protein kinase C inhibitors
DE9320226U1 (de) Lesehilfe
DE9312948U1 (de) Durchleuchter
CY2007006I2 (el) Αναστολεις συνθεσεις απολιποπρωτεϊνης-β

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN